Información de Bristol-Myers Squibb Co, dividendo de Bristol-Myers Squibb Co, actividades de los accionistas y más

Información de Bristol-Myers Squibb Co Compañía

Información de la empresa

Código de la empresaBMY

Nombre de la empresaBristol-Myers Squibb Co

Fecha de salida a bolsaJul 05, 1929

Fundada en1933

Director ejecutivoDr. Christopher S. (Chris) Boerner, Ph.D.

Número de empleados34100

Tipo de títulosOrdinary Share

Fin del año fiscalJul 05

DirecciónRoute 206 And Province Line Road

CiudadPRINCETON

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal08543

Teléfono16092524621

Sitio Webhttps://www.bms.com/in

Código de la empresaBMY

Fecha de salida a bolsaJul 05, 1929

Fundada en1933

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionados

Cambio

Ms. Sandra Leung

Executive Vice President, General Counsel, Member of the Leadership Team

448.10K

+6.18%

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer, Chief Operating Officer

104.62K

+1.95%

Mr. Samit Hirawat, M.D.

Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team

63.93K

+2.94%

Dr. Julia A. Haller, M.D.

Independent Director

13.61K

--

Mr. Phil Holzer

Senior Vice President, Controller

11.76K

-5.62%

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

6.65K

+1.16K%

Ms. Karin Shanahan

Executive Vice President, Global Product Development & Supply, Member of the Leadership Team

5.33K

+65.41%

Ms. Cari Gallman

Executive Vice President, Corporate Affairs, Member of the Leadership Team

5.01K

+137.97%

Mr. Robert Plenge, M.D., Ph.D.

Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team

--

Mr. Peter J. (Pete) Arduini

Independent Director

--

Nombre

Nombre/Posición

Posición

Accionados

Cambio

Ms. Sandra Leung

Executive Vice President, General Counsel, Member of the Leadership Team

448.10K

+6.18%

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer, Chief Operating Officer

104.62K

+1.95%

Mr. Samit Hirawat, M.D.

Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team

63.93K

+2.94%

Dr. Julia A. Haller, M.D.

Independent Director

13.61K

--

Mr. Phil Holzer

Senior Vice President, Controller

11.76K

-5.62%

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

6.65K

+1.16K%

Desglose de ingresos

Divisa: USDHora de actualización: mié., 5 de mar

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por negocioUSD

Nombre

Ganancia

Proporción

Eliquis

13.33B

27.60%

Opdivo

9.30B

19.26%

Revlimid

5.77B

11.95%

Orencia

3.68B

7.62%

Pomalyst/Imnovid

3.54B

7.33%

Other

12.66B

26.21%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

34.10B

70.61%

International

13.19B

27.32%

other

996.00M

2.06%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Eliquis

13.33B

27.60%

Opdivo

9.30B

19.26%

Revlimid

5.77B

11.95%

Orencia

3.68B

7.62%

Pomalyst/Imnovid

3.54B

7.33%

Other

12.66B

26.21%

Accionista

Hora de actualización: vie., 21 de feb

Estadísticas de accionistas

Tipo

Estadísticas de accionistas

Accionista

Proporción

The Vanguard Group, Inc.

9.31%

BlackRock Institutional Trust Company, N.A.

4.78%

State Street Global Advisors (US)

4.68%

JP Morgan Asset Management

3.10%

Charles Schwab Investment Management, Inc.

2.97%

Other

75.13%

Estadísticas de accionistas

Accionista

Proporción

The Vanguard Group, Inc.

9.31%

BlackRock Institutional Trust Company, N.A.

4.78%

State Street Global Advisors (US)

4.68%

JP Morgan Asset Management

3.10%

Charles Schwab Investment Management, Inc.

2.97%

Other

75.13%

Tipo

Accionista

Proporción

Investment Advisor

36.81%

Investment Advisor/Hedge Fund

32.60%

Research Firm

2.76%

Pension Fund

2.50%

Bank and Trust

2.25%

Sovereign Wealth Fund

1.85%

Hedge Fund

1.70%

Holding Company

0.23%

Insurance Company

0.16%

Other

19.10%

Participación institucional

Hora de actualización: dom., 19 de ene

Periodo de informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q1

4136

1.64B

81.10%

+16.36M

2024Q4

4261

1.64B

81.14%

+17.04M

2024Q3

4116

1.59B

78.69%

-22.72M

2024Q2

4105

1.58B

78.35%

-83.11M

2024Q1

4118

1.64B

80.97%

+13.32M

2023Q4

4115

1.60B

78.83%

-46.38M

2023Q3

4042

1.62B

77.83%

-55.49M

2023Q2

4082

1.65B

78.77%

-34.93M

2023Q1

4110

1.65B

78.74%

-34.09M

2022Q4

4105

1.65B

77.92%

-72.60M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

189.01M

9.31%

+1.40M

+0.74%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

97.01M

4.78%

-7.45M

-7.13%

Dec 31, 2024

State Street Global Advisors (US)

95.14M

4.68%

+2.24M

+2.42%

Dec 31, 2024

JP Morgan Asset Management

63.09M

3.1%

+12.35M

+24.34%

Dec 31, 2024

Charles Schwab Investment Management, Inc.

60.30M

2.97%

-729.92K

-1.19%

Dec 31, 2024

Capital International Investors

45.86M

2.26%

+3.21M

+7.54%

Dec 31, 2024

Geode Capital Management, L.L.C.

44.39M

2.18%

+1.18M

+2.74%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

35.17M

1.73%

+2.58M

+7.91%

Dec 31, 2024

Columbia Threadneedle Investments (US)

28.49M

1.4%

+12.26M

+75.54%

Dec 31, 2024

Fidelity Management & Research Company LLC

27.55M

1.35%

-9.07M

-24.77%

Dec 31, 2024

ETF relacionados

Hora de actualización: hace 15 horas

Nombre

Proporción

First Trust NASDAQ Pharmaceuticals ETF

8.03%

Invesco S&P Ultra Dividend Revenue ETF

6.78%

NYLI Healthy Hearts ETF

4.96%

iShares U.S. Pharmaceuticals ETF

4.8%

Invesco Pharmaceuticals ETF

4.79%

VanEck Morningstar Wide Moat Value ETF

4.58%

VanEck Pharmaceutical ETF

4.37%

Schwab U.S. Dividend Equity ETF

4.3%

Cullen Enhanced Equity Income ETF

3.79%

SPDR S&P Pharmaceuticals ETF

3.67%

First Trust NASDAQ Pharmaceuticals ETF

Proporción8.03%

Invesco S&P Ultra Dividend Revenue ETF

Proporción6.78%

NYLI Healthy Hearts ETF

Proporción4.96%

iShares U.S. Pharmaceuticals ETF

Proporción4.8%

Invesco Pharmaceuticals ETF

Proporción4.79%

VanEck Morningstar Wide Moat Value ETF

Proporción4.58%

VanEck Pharmaceutical ETF

Proporción4.37%

Schwab U.S. Dividend Equity ETF

Proporción4.3%

Cullen Enhanced Equity Income ETF

Proporción3.79%

SPDR S&P Pharmaceuticals ETF

Proporción3.67%

Dividendos

Un total de 22.71B USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Dec 11, 2024

BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option

Jan 03, 2025

Feb 03, 2025

Jan 03, 2025

Sep 10, 2024

BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option

Oct 04, 2024

Nov 01, 2024

Oct 04, 2024

Jun 18, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option

Jul 05, 2024

Aug 01, 2024

Jul 05, 2024

Mar 01, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option

Apr 05, 2024

May 01, 2024

Apr 04, 2024

Dec 06, 2023

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option

Jan 05, 2024

Feb 01, 2024

Jan 04, 2024

Sep 20, 2023

BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023

Oct 06, 2023

Nov 01, 2023

Oct 05, 2023

Jun 14, 2023

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option

Jul 07, 2023

Aug 01, 2023

Jul 06, 2023

Mar 03, 2023

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023

Apr 10, 2023

May 01, 2023

Apr 06, 2023

Dec 08, 2022

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023

Jan 06, 2023

Feb 01, 2023

Jan 05, 2023

Sep 14, 2022

BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022

Oct 07, 2022

Nov 01, 2022

Oct 06, 2022

División de acciones

Fecha

Tipo

Relación

No datos encontrados

Fecha

Tipo

Relación

No datos encontrados

Bristol-Myers Squibb Co

60.180USD

Bristol-Myers Squibb Co

60.180

Descripción general

Compañía